Niemann Pick Type C Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2031
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Niemann-Pick Disease Type C (NPC) Market Overview
Niemann-Pick disease type C (NPC) is a rare progressive genetic disorder, a form of lysosomal storage disorder, that is characterized by an inability of the body to conduct intracellular transport of cholesterol and other lipids, leading to the abnormal accumulation of these substances within various bodily tissues including brain tissue. NPC is highly variable, and the age of onset and specific symptoms can vary, ranging from a fatal disorder within the first few months after birth (neonatal period) to a late-onset, chronic progressive disorder that remains undiagnosed well into adulthood.
The NPC market research report offers an overview of NPC, including its epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying smart business strategies. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.
Buy the Full Report to Know More about the NPC Market
Download a Free Sample Report
| Key Countries (8MM) | · The US
· Germany · UK |
| Key Drug Classes | · Zavesca
· Yargesa · Miglustat |
| Key Sponsors | · IntraBio Ltd.
· Zevra Therapeutics · Cyclo Therapeutics Inc. · Azafaros |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
NPC Market Drivers
The NPC market is expected to have several novel entrants across the forecast period. These include cyclodextrin therapy Trappsol Cyclo, the calcium ion channel regulator acetylleucine, the heat shock protein activator arimoclomol citrate ER, and glucosylceramide synthase inhibitor nizubaglustat.
Buy the Full Report for Additional Driver Insights on the Key NPC Market
Download a Free Sample Report
NPC Market Segmentation by Countries
The key countries in the NPC market are the US, Germany, and the UK. In 2021, the US dominated the total NPC market share followed by Germany & the UK.
NPC Market Analysis by Countries, 2021 (%)
Buy the Full Report for Country-Wise Insights on the NPC Market
Download a Free Sample Report
NPC Market Segmentation by Drugs
The drug classes in the NPC market include Zavesca, Yargesa, and Miglustat among others. In 2021, Zavesca contributed the highest sales to the NPC market.
NPC Market Analysis by Drug Classes, 2019 (%)
Buy the Full Report for Drug Insights on the NPC Market
Download a Free Sample Report
NPC Market Segmentation by Sponsors
The key sponsors in the NPC market are IntraBio Ltd., Zevra Therapeutics, Cyclo Therapeutics Inc., and Azafaros.
NPC Market Analysis by Sponsors

Buy the Full Report for Sponsor Insights on the NPC Market
Download a Free Sample Report
Segments Covered in this Report
NPC Market Country Outlook (2021-2031)
- The US
- Germany
- UK
NPC Market Drug Outlook (2021-2031)
- Zavesca
- Yargesa
- Miglustat
Scope
The report provides:
- Overview of NPC, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized NPC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the ALS market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ALS. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 8MM ALS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a PowerPoint report and Excel-based forecast model
Forecast includes three countries: US, Germany and the UK
Forecasts cover three time points: base year, 5-year, and 10-year
The prevalence of Niemann Pick Type C (NPC) is increasing at a steady rate, in line with population growth in the 3MM at an AGR of 0.29%.
Currently, the treatment regimen for NPC in the 3MM is entirely limited to the use of miglustat (Yargesa, Zavesca or generic).
There are several unmet needs in this space, including therapies with low or minimal toxicity and novel therapies with improved efficacy.
The NPC late-stage R&D pipeline is focused on developing medicines with different mechanisms of action.
Steady growth is expected throughout the forecast period as the NPC population steadily increases and novel therapies enter the market.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 8MM ALS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ALS therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Piramal Enterprises
IntraBio Ltd.
Zevra Therapeutics
Azafaros
Cyclo Therapeutics Inc.
Table of Contents
Frequently asked questions
-
Which was the leading country in the NPC market in 2021?
In 2021, the US dominated the total NPC market.
-
Which was the leading drug class in the NPC market in 2021?
In 2021, the Zavesca drug contributed the highest sales to the NPC market.
-
Which are the leading sponsors in the NPC market?
The key sponsors in the NPC market are IntraBio Ltd., Zevra Therapeutics, Cyclo Therapeutics Inc., and Azafaros.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports